The Paul Ehrlich Institute (PEI) has approved expansion of the global INVISE Phase 1 clinical trial to Europe. The study aims to evaluate first-in-class gene therapy for the treatment of B-cell malignancies.
https://european-biotechnology.com/wp-content/uploads/2025/01/gr3_lrg-scaled-e1736501313476.jpg600960Christian Kähler/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngChristian Kähler2025-01-13 09:42:232025-01-13 09:42:23First in vivo CAR gene therapy trial in Europe approved